

# ASX Announcement

22 March 2021

## InvestorStream Interview - Presentation

AnteoTech Ltd (ASX: ADO) ("AnteoTech" or "the Company") is pleased to provide a copy of the presentation by CEO Derek Thomson for the InvestorStream interview.

The interview is available at:

<https://www.investorstream.com.au/anteotech-release-march>

This announcement has been authorised for release by the Board.

**For more information, please contact:**

Friederike Graser, Communications Manager, AnteoTech Ltd: +61 (0) 7 3219 0085

Ben Jarvis, Six Degrees Investor Relations: +61 (0) 413 150 448

**ABOUT ANTEO GROUP – AnteoTech Ltd (ASX:ADO)**

AnteoTech is a surface chemistry company with Intellectual Property ("IP") in its core technology product groups AnteoCoat™, AnteoBind™ and AnteoRelease™. The Company's purpose is to create shareholder value by identifying and solving important global industry problems by providing unique value-add solutions for its customers. Customers operate in the life sciences, diagnostics, energy and medical devices markets.

Follow AnteoTech on Twitter: <https://twitter.com/AnteoTech> or visit [www.anteotech.com](http://www.anteotech.com)



For personal use only



**AnteoTech**

**Investor Stream Interview**

**Life Science Timeline - CE Mark and Beyond**

**AnteoTech Ltd (ASX:ADO)**

**Derek Thomson, CEO**

**22 March 2021**

# ANTEOTECH INVESTOR HIGHLIGHTS



## Diversified investment opportunity with high growth potential in high impact sectors

|  |   |  |
|--|---|--|
|  | <b>Unique, proprietary</b> nano-polymer technology              | Proven product AnteoBind in market – Integrated in Ellume Home Test - FDA EUA<br>Proof of concept delivered across <b>Life Science &amp; Energy</b> applications<br>Supported by established suite of IP protection  |
|  | Active in <b>Growth</b> markets                                 | <b>Life Science</b> - Lateral Flow Assay (LFA) Market grow to <b>US\$8.7b by 2023 - 7.7% CAGR 2019-2023<sup>1</sup></b><br><b>Energy</b> - Silicon materials market growing by <b>34% CAGR by 2030<sup>1</sup></b> in a Lithium battery market growing to +\$100 billion 2030 <sup>2</sup>   |
|  | <b>Developing solutions</b> in high growth, high impact sectors | Improving <b>Point-Of-Care (POC)</b> testing & assay development in diagnostics, drug development<br><b>Maximising growth in POC</b> by leveraging diagnostic platform across of new test development, market segment and data opportunities<br>Improving <b>lithium-ion battery energy storage</b> as a result of enhanced silicon integration<br>High potential for future application of technology in other sectors            |
|  | <b>Ready to deliver</b> – short to medium term opportunity      | <b>~1-3 Months</b> - AnteoTech COVID-19 Antigen Rapid Test in EU and Australian markets<br><b>~6-9 Months</b> - COVID-19 & Flu A/B test in late-stage development for US / N. Hemisphere Flu<br><b>~6-9 Months</b> - Increasing AnteoBind sale through Ellume ramp up<br><b>~12 Months</b> - Sepsis detection test in early pre-clinical development<br><b>~12 Months</b> - Commercialisation of AnteoX into battery binder market |
|  | <b>Capital Structure</b><br>@31/12/20                           | <b>Revenues:</b> \$0.6 million for H1/FY21 505% growth YoY<br><b>Cash:</b> \$6.4M <b>Debt:</b> Nil <b>Shares on issue:</b> 1.87 billion  |


<sup>1</sup> Market Forecast: "Lateral Flow Assay Market by Application,Product, Technique, End User - Global Forecast to 2023" ResearchAndMarkets.com

<sup>2</sup> Source: Rechargeable Battery Market Main Trends 2017-2030, Avicenne Energy

Personal use only

# WHAT SETS ANTEOTECH'S TECHNOLOGY APART

Combining AnteoBind technology with activated Europium achieves the high sensitivity needed for COVID-19




All tests to be developed on this platform use this technology

1. Internal product development validation. 2. ThermoFisher Scientific Product Specification: Fluoro-Max Fluorescent Beads With Europium Chelate

ersonal use only


# ANTICIPATED DEVELOPMENT TIMELINE 2021




1. Operon - Manufacturing presence in Spain for COVID-19 ART 2. VIDRL - Victorian Infectious Diseases Reference Laboratory  
 3. CE Mark is a requirement for EU market, denotes product meets all EU Medical Device Directives

# ANTEOBIND & LATERAL FLOW TEST PRINCIPLES

## Lateral Flow Test Model



Protein-Particle Conjugate for detection in the test is the key component that impacts an assay performance



Imaging of an antibody conjugated, AnteoBind™ activated europium particle

# GLOBAL CHALLENGE OF SEPSIS

- Sepsis: preventable, life-threatening condition marked by severe organ dysfunction.
- 2017 studies estimate **49 million** cases and **11 million sepsis-related** deaths worldwide; accounting for 20% of all global deaths
- **Early diagnosis** & timely clinical management are crucial to increase likelihood of survival
- Guidelines recommend antibiotic therapy within **one hour of suspected sepsis**. With each hour antibiotic therapy is delayed, survival **decreases by about 8%**.<sup>1</sup>
- Disproportionately affects neonates, pregnant or recently-pregnant women, and people living in low-resource settings. ~85% sepsis cases and deaths occur in these settings.
- Sepsis frequently results from infections acquired in healthcare settings – **1 in 4 cases of sepsis in hospitals** and **1 in 2 cases of sepsis in ICUs** result from healthcare-associated infections.
- World Health Assembly declared combating sepsis a global priority in 2017 and addressing impact will significantly contribute to achieving Sustainable Development Goals on Health

**~ 20%**  
global deaths  
due to sepsis

**'Rapid, affordable and appropriate diagnostic tools, particularly for primary and secondary levels of care, are needed to improve sepsis identification, surveillance, prevention and treatment.'**

WHO Global Report on Epidemiology and Burden of Sepsis, Sep 2020

Source: World Health Organisation Global Report on Sepsis, September 2020

<sup>1</sup> Early Recognition and Management of Sepsis in Adults: The First Six Hours (Am Fam Physician. 2013 Jul 1;88(1):44-53.)

# LEVERAGING CURRENT DEVELOPMENT

Investment in the current test platform could instigate a number of leverage plays that will **accelerate revenue**

## Current Tests

- COVID-19
- COVID-19 Flu A&B
- Sepsis

## Leverage test development capability to produce future tests including potential for:

- COVID-19 antibody
- Infectious diseases
- Bacterial diseases
- Viral conditions
- Cardiac conditions



## Test suite enabled on different reader platforms designed for market segments

- In field testing – military / refugee / care org.
- Mining / oil & gas / remote location medical services
- At home testing
- Low- and middle-income country testing

## Quantitative Clinical Decision Support

- Enhanced quantitative detection algorithms
- Leverage patient data banks
- More accurate clinical intervention decision support



ersonal use only